The Latest Cardiac and Vascular News
– Patients successfully self-managed PSVT episodes with etripamil which reduced need for ED intervention – – As in other studies, etripamil was well tolerated by patients – – Data to be featured during late breaking session at Heart Rhythm 2022 – MONTREAL and CHARLOTTE, N.C., April 30, 2022 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), […]
MONTREAL and CHARLOTTE, N.C., April 15, 2022 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Milestone’s Compensation Committee granted one new employee 65,000 incentive stock options at a per share exercise price of $6.85, the closing price of Milestone’s common stock on April […]
– RAPID topline data readout expected mid-second half 2022 MONTREAL and CHARLOTTE, N.C., March 24, 2022 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a clinical and corporate update. “2021 was […]
MONTREAL and CHARLOTTE, N.C., Feb. 16, 2022 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer, effective February 15, 2022. Dr. Bharucha is a cardiac electrophysiologist who brings to Milestone over thirty years of […]
– Etripamil significantly decreased heart rate during SVT episodes and independent of conversion to SR – – HR changes occurred within 5 minutes and were sustained for 60 minutes – – Data presented at AHA Scientific Sessions 2021 – MONTREAL and CHARLOTTE, N.C., Nov. 15, 2021 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical […]
MONTREAL and CHARLOTTE, N.C., Nov. 12, 2021 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended September 30, 2021 and provided a clinical and corporate update. “We continue to make meaningful progress across our etripamil PSVT program. We’ve […]
MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2021 and provided a clinical, regulatory, and corporate update. “We continue to work closely with our existing clinical trial sites, […]
MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the first patient has been enrolled in its Phase 2 proof-of-concept study of etripamil nasal spray for the Reduction of Ventricular Rate in patients experiencing Atrial fibrillation and rapid ventricular rate (AFib-RVR), […]
MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a clinical and corporate update. “We are keenly focused on executing on our etripamil development […]
MONTREAL and CHARLOTTE, N.C., Nov. 13, 2020 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended September 30, 2020 and provided a clinical and corporate update. “We remain on track to reopen enrollment in the pivotal Phase 3 […]
